APA
Click to copy
Aguilera, X., González, C., Apablaza, M., Rubilar, P., Icaza, G., Ramírez-Santana, M., … Vial, P. M. (2022). Immunization and SARS-CoV-2 Antibody Seroprevalence in a Country with High Vaccination Coverage: Lessons from Chile. Vaccines.
Chicago/Turabian
Click to copy
Aguilera, X., Claudia González, M. Apablaza, Paola Rubilar, G. Icaza, M. Ramírez-Santana, C. Pérez, et al. “Immunization and SARS-CoV-2 Antibody Seroprevalence in a Country with High Vaccination Coverage: Lessons from Chile.” Vaccines (2022).
MLA
Click to copy
Aguilera, X., et al. “Immunization and SARS-CoV-2 Antibody Seroprevalence in a Country with High Vaccination Coverage: Lessons from Chile.” Vaccines, 2022.
BibTeX Click to copy
@article{x2022a,
title = {Immunization and SARS-CoV-2 Antibody Seroprevalence in a Country with High Vaccination Coverage: Lessons from Chile},
year = {2022},
journal = {Vaccines},
author = {Aguilera, X. and González, Claudia and Apablaza, M. and Rubilar, Paola and Icaza, G. and Ramírez-Santana, M. and Pérez, C. and Cortes, L. J. and Núñez-Franz, Loreto and Quezada-Gaete, R. and Castillo-Laborde, Carla and Correa, Juan and Said, Macarena and Hormazábal, Juan and Vial, C. and Vial, Pablo M.}
}
Chile is among the most successful nations worldwide in terms of its COVID-19 vaccine rollout. By 31 December 2021, 84.1% of the population was fully vaccinated, and 56.1% received booster doses using different COVID-19 vaccines. In this context, we aimed to estimate the prevalence of anti-SARS-CoV-2 antibodies following the infection and vaccination campaign. Using a three-stage stratified sampling, we performed a population-based cross-sectional serosurvey based on a representative sample of three Chilean cities. Selected participants were blood-sampled on-site and answered a short COVID-19 and vaccination history questionnaire using Wantai SARS-CoV-2 Ab ELISA to determine seroprevalence. We recruited 2198 individuals aged 7–93 between 5 October and 25 November 2021; 2132 individuals received COVID-19 vaccinations (97%), 67 (3.1%) received one dose, 2065 (93.9%) received two doses, and 936 received the booster jab (42.6%). Antibody seroprevalence reached 97.3%, ranging from 40.9% among those not vaccinated to 99.8% in those with booster doses (OR = 674.6, 154.8–2938.5). SARS-CoV-2 antibodies were associated with vaccination, previous COVID-19 diagnosis, age group, and city of residence. In contrast, we found no significant differences in the type of vaccine used, education, nationality, or type of health insurance. We found a seroprevalence close to 100%, primarily due to the successful vaccination program, which strongly emphasizes universal access.